# MVRIX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mvrix

- Industry: Biotechnology
- Headquarters: Hwaseong, South Korea
- Website: www.mvrix.co.kr/
- Total disclosed funding: $5.9M
- Latest round: Series B (Sep 4, 2026)
- Investors on record: 5

## About

Based in Gyeonggi, South Korea, and founded in 2021 MVRIX Co., Ltd.. doing business as MVRIX, with a mission to develop innovative therapeutics through advanced biotechnology and protein-engineering research. Since its establishment, the company has rapidly built three core platform technologies and expanded its network through collaborations with companies, universities, and research institutes. MVRIX specializes in targeted mRNA delivery, in vivo CAR-T therapies, recombinant botulinum toxins, and biologics development. The company has accumulated a substantial patent portfolio and has received multiple government-backed R&D and startup support programs. Its most recent funding round was a Series B financing of KRW 8 billion completed in September 2026.
The company focuses on developing next-generation therapeutic platforms based on protein engineering and gene therapy technologies. Its flagship technologies include the Navibody Platform, which enables targeted mRNA delivery with enhanced specificity and manufacturing efficiency; the In vivo CAR-T Platform, designed to realize next-generation cell therapies directly within the body; and the rBoNT Platform, a recombinant botulinum toxin technology aimed at creating faster, safer, and longer-lasting toxin therapeutics. In addition, MVRIX conducts research in biologics discovery, gene therapy delivery systems, and novel therapeutic modalities.
The company's revenue is generated through the development and commercialization of proprietary biotechnology platforms, research collaborations, licensing agreements, technology transfer transactions, and future commercialization of therapeutic candidates. A notable example is the licensing-out agreement of its MBT-002 recombinant botulinum toxin pipeline to Eyegene in 2025, demonstrating the company's strategy of monetizing its platform technologies through partnerships and licensing deals.
The company will use the funding to accelerate the development and commercialization of its targeted mRNA delivery and in vivo CAR-T platforms, advance preclinical and clinical programs, strengthen its proprietary biotechnology pipeline, and expand its position in next-generation gene therapy.

## Funding rounds

- Series B, Sep 4, 2026, $5.9M — InterVest, Korea Investment Partners, EyeGene, Korea Omega Investment Corp., Seoul Technology Holdings

## Investors

- InterVest (https://capitalatlas.ai/funds/intervest) — Series B
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series B
- EyeGene — Series B
- Korea Omega Investment Corp. (https://capitalatlas.ai/funds/korea-omega-investment-corp) — Series B
- Seoul Technology Holdings (https://capitalatlas.ai/funds/seoul-technology-holdings) — Series B